Zydus Lifesciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Zydus Lifesciences Ltd reported a 10.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.8%.
• Its expenses for the quarter were up by 2.3% QoQ and 20.1% YoY.
• The net profit increased 31.1% QoQ and increased 7.8% YoY.
• The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 12.65 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Zydus Lifesciences Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company is known for its emphasis on research and development to enhance its product offerings and maintain competitiveness. Zydus Lifesciences Ltd operates in various segments, including generics and branded formulations, biologics, vaccines, and animal health. The company has established a significant presence in both domestic and international markets. While there might be recent developments or strategic initiatives undertaken by Zydus Lifesciences Ltd, specific details beyond the provided financial data are not available.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Zydus Lifesciences Ltd reported a total income of ₹7721.20 crores. This represents a quarter-over-quarter (QoQ) increase of 10.7% compared to ₹6975.90 crores in Q3FY26. Year-over-year (YoY), the total income showed a growth of 16.8% from ₹6608.50 crores in Q4FY25. This upward trend in revenue indicates a consistent increase in the company's top-line performance over the past year. The financial data underscores the company's ability to generate higher sales, contributing to its overall income growth during this period.

Profitability

Zydus Lifesciences Ltd's profitability metrics demonstrate a positive trend in Q4FY26. The company achieved a profit before tax (PBT) of ₹1659.70 crores, marking a QoQ increase of 22.6% from ₹1353.40 crores in Q3FY26. However, the PBT showed a slight YoY decrease of 0.7% from ₹1672.00 crores in Q4FY25. The tax expense for Q4FY26 was ₹318.40 crores, which decreased by 18.0% QoQ and 24.8% YoY. Consequently, the profit after tax (PAT) rose to ₹1341.00 crores, reflecting a QoQ increase of 31.1% and a YoY growth of 7.8%. The company's earnings per share (EPS) also improved, reaching ₹12.65 in Q4FY26, a rise of 22.1% QoQ and 8.7% YoY. These figures highlight the company's ability to enhance its profitability despite fluctuations in tax obligations.

Operating Metrics

The fourth quarter of the fiscal year 2026 saw Zydus Lifesciences Ltd managing its operational expenses effectively. Total expenses amounted to ₹5664.00 crores, with a marginal QoQ increase of 2.3% when compared to ₹5537.60 crores in Q3FY26. On a YoY basis, total expenses rose by 20.1% from ₹4716.90 crores in Q4FY25. The relatively moderate increase in expenses alongside substantial revenue growth suggests a strong operational performance. The company's focus on controlling expenses has contributed to maintaining solid operating metrics, supporting its overall financial health during the period under review.